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The neuronal ceroid lipofuscinoses (NCLs) are inherited lysosomal storage disorders 
characterised by general neurodegeneration and premature death. Sight loss is also a 
major symptom in NCLs, severely affecting the quality of life of patients but is not 
targeted effectively by brain-directed therapies. Here, we set out to explore the 
therapeutic potential of an ocular gene therapy to treat sight loss in NCL due to a 
deficiency in the transmembrane protein CLN6. We found that although Cln6nclf mice 
presented mainly with photoreceptor degeneration, supplementation of CLN6 in 
photoreceptors was not beneficial. Because the level of CLN6 is low in photoreceptors, 
but high in bipolar cells, retinal interneurons that are only lost in Cln6-deficient mice 
at late disease stages, we explored the therapeutic effects of delivering CLN6 to bipolar 
cells using AAV serotype 7m8. Bipolar cell-specific expression of CLN6 slowed 
significantly the loss of photoreceptor function and photoreceptor cells. This study 
shows that the deficiency of a gene normally expressed in bipolar cells can cause the 








The neuronal ceroid lipofuscinoses (NCLs) are rare, inherited lysosomal storage 
disorders that present with severe neurodegeneration and sight loss. This group of 
diseases is more commonly referred to as Batten disease and at least 13 genes have 
been linked to the development of this condition with a combined incidence in different 
countries of between 1:12,500 and 1:100,0001. The affected genes code either for a 
soluble lysosomal protein or a transmembrane protein2. The development of therapies 
for forms of NCL caused by defects in lysosomal enzymes is aided by lysosomal cross-
correction, which allows the therapeutic enzyme to be taken up by cells from the 
circulation and other cells via the mannose-6-phosphate pathway3. This phenomenon 
has helped to pave the way towards clinical trials for CLN2 disease, a common form of 
NCL arising from the deficiency in the lysosomal enzyme TPP1 (NCT01907087). 
Cross-correction, however, does not occur for transmembrane proteins, limiting 
functional restoration to individual cells and increasing the challenge to achieve a 
therapeutic effect.  
 
CLN3 disease with juvenile onset is the most common form of NCL that is caused by 
a defect in a membrane-bound protein4. Other rarer forms caused by transmembrane 
protein deficiencies include CLN6, CLN7 and CLN8 disease, all variant forms with 
typically a late-infantile onset and a more rapid progression than CLN3 disease. NCLs 
usually manifest with seizures, visual decline resulting in blindness, progressive 
psychomotor and cognitive deteriorations. The order of the symptoms varies, yet these 
conditions collectively lead to premature death5. A major obstacle to developing brain-
directed therapies for NCLs arising from transmembrane protein defects is the 
challenge to deliver agents throughout the brain. Recently, the partial rescue of the brain 
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phenotype in a CLN3 disease mouse model was described following brain-directed 
adeno-associated virus (AAV)-mediated gene therapies6,7. No correction of the disease 
pathology was reported outside of the brain underlining the need for treatments not only 
targeting the brain but also other affected organs like the eye. Moreover, ocular 
therapies may not only increase the quality of life of patients but may also help with 
the development of brain-directed treatments for NCLs. 
 
Over the last decade, AAV-mediated gene therapies have been used for several animal 
models of monogenic retinal degenerations to restore the expression of soluble or 
transmembrane proteins and to treat vision loss8-10. These encouraging studies led to 
the commencement of clinical trials for inherited retinal degenerative conditions 
including Leber congenital amaurosis11-13 and retinitis pigmentosa14. Here, we explored 
the therapeutic potential of an ocular AAV-mediated gene therapy in the Cln6nclf mouse, 
a naturally occurring model of CLN6 disease, variant late-infantile. The mice carry a 1 
bp insertion mutation in the Cln6 gene which encodes a membrane-bound ER protein 
of unknown function15. The 1 bp insertion results in a frameshift and a truncated short-
lived protein product and is also found in CLN6 patients of Pakistani origin16,17. Cln6nclf 
mice present with loss of vision preceding severe neuropathological and behavioural 
abnormalities18,19.  
 
In this study we show that although retinal disease in Cln6nclf mice is predominately 
characterised by photoreceptor degeneration, supplementation of CLN6 in 
photoreceptors is not therapeutic. We also establish that in unaffected retinas, CLN6 is 
expressed in photoreceptors and bipolar cells but the level is much higher in bipolar 
cells. Although bipolar cells are only lost late in disease, AAV-mediated gene delivery 
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of CLN6 to bipolar cells, leads to significantly increased retinal function and long-term 
preservation of photoreceptors. This study shows that photoreceptor degeneration can 
be prevented by treating bipolar cells.  
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Results 
CLN6 is more highly expressed in bipolar cells than in photoreceptors  
To determine the potential target cells for gene therapy, we investigated the endogenous 
expression of the CLN6 gene in human and mouse retina. Due to the lack of antibodies 
against the murine protein we performed immunohistochemical stainings on human 
retina from non-diseased donor eyes using a previously reported antiserum against 
human CLN615. We detected a weak fluorescent signal in the ONL and a strong 
fluorescent signal in the INL (Figure 1A, 1B, 1B’’). In the INL the staining for CLN6 
co-localised with staining for PKCα, demonstrating that rod bipolar cells express CLN6 
(Figure 1B, 1B’, Figure S2A-B’). Co-staining with an antibody against CRALBP, a 
marker for Mueller glia cells, did not reveal any co-localisation (Figure S2A, S2A’). In 
the absence of antibodies that could be used for co-localisation with CLN6 staining, we 
were unable to determine what other cell types in the INL expressed the gene. 
Microarray data on the murine retina suggests that the remaining CLN6-positive cells 
are most likely to be other bipolar cell types, as rod bipolar cells only form a minor 
fraction of the retinal bipolar cell population20. 
Cln6nclf mice have been reported to present with a predominant loss of photoreceptor 
function and photoreceptor cells18,19. We found that from postnatal day 21 (P21), retinal 
function in Cln6-deficient mice was progressively compromised under scotopic light 
conditions as measured by electroretinography (ERG) recordings (Figure S1A, S1C, 
S1D). The photopic ERG was unchanged (Figure S1B). Histological assessment and 
quantitative analyses of the outer nuclear layer (ONL) revealed no severe histological 
changes at P14 (Figure S1E, S1F). However, Cln6nclf mice have a significantly reduced 
number of photoreceptor nuclei at 1 and 6 months compared with wild type controls 
(Figure S1G, S1H). The number of rod bipolar cells in the inner nuclear layer (INL) 
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was only reduced in mutant mice at 6 months (p<0.001) (Figure S1I, S1J). In line with 
previous reports these data show that Cln6nclf mice suffer from an early but mildly 
progressing rod-mediated retinal degeneration, whilst loss of rod bipolar cells became 
only evident at late disease stages.  
In the murine retina we assessed the expression of Cln6 by quantitative real-time PCR 
(qRT-PCR). To confirm the expression of Cln6 in murine photoreceptors and bipolar 
cells, we performed qRT-PCRs on mRNA obtained from fluorescence-activated cell 
sorted (FACS) photoreceptors, labelled with the cell surface marker CD73, and rod 
bipolar cells, labelled with td.tomato in a Pcp2.Cre/td.tomato mouse line (Figure S2B, 
S2C). In line with the staining on human retina, we found a trend with a higher 
expression level of Cln6 in rod bipolar cells than in photoreceptors (Figure 1C). A direct 
comparison of the absolute number of mRNA molecules by qRT-PCR showed that 
Cln6 was expressed to similarly high levels in whole mouse retina as the photoreceptor-
specific gene Peripherin2, encoding a highly abundant retinal protein21 (Figure 1D). 
We studied the relative expression level of Cln6 in the retina over time using qRT-PCR 
and found that Cln6 was expressed from birth to adulthood. From P0 to P14, a period 
when retinal cells undergo postnatal maturation leading to initiation of the 
phototransduction cascade and eye opening, the expression level of Cln6 was relatively 
stable at around 50 % of adult levels. At P21 the expression level of Cln6 increased to 
the level that was detected in adults (Figure 1E), which may indicate that Cln6 could 




AAV2/8-mediated supplementation of CLN6 in photoreceptors is not therapeutic in 
Cln6nclf mice 
We established that CLN6 was expressed in photoreceptors and that Cln6 deficiency 
led to severe loss of photoreceptors in mice, while no early death of bipolar cells was 
detected in Cln6nclf mice despite the high endogenous expression level of CLN6 in 
bipolar cells. Consequently, we set out to develop a gene supplementation therapy 
targeting photoreceptors and treated pre-symptomatic P9-P10 Cln6nclf mice subretinally 
with an AAV2/8 vector carrying the ubiquitous CMV promoter and the human CLN6 
(hCLN6) transgene (Figure S3). We administered three different doses ranging from 
1.5x108 vg/eye to 1.5x1010 vg/eye and performed ERG recordings at 1, 2, 4 and 6 
months of age. As untreated Cln6nclf mice presented with a progressive reduction in rod 
photoreceptor function, the main functional readout to assess whether the treatment was 
successful was the scotopic a-wave. None of the treated animals had significantly 
higher a-wave amplitudes than the untreated or AAV2/8.null vector-treated mutant 
animals at any time point (Figure 2A). Immunostaining confirmed the presence of the 
transgene at 6 months. In line with the ERG recordings, the ONL did not appear to be 
preserved in any of the treated eyes (Figure 2B-2D’, Figure S1G). Further experiments 
targeting the photoreceptor cells, including earlier treatment at P5 and use of a weak 
photoreceptor-specific mouse opsin promoter22, did not preserve photoreceptor 
function or improve photoreceptor survival. Since the human and mouse CLN6 protein 
share about 90% amino acid identity, we also assessed the efficacy of AAV8 carrying 
mouse Cln6 and a CMV promoter to exclude that slight differences in the amino acid 
sequence between human and mouse CLN6 could affect the outcome of the treatment. 
No treatment effect was observed (Table S1). These experiments demonstrated that an 
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AAV-mediated gene supplementation therapy targeting photoreceptor cells was not 
therapeutic in Cln6-deficient mice.   
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The AAV2/2 variant 7m8 transduces bipolar cells efficiently in wild type mice 
Conventional AAV serotypes poorly transduce cells in the INL and bipolar cells are 
amongst the cell types least amenable to viral transduction23. Several studies have been 
undertaken to engineer AAV vectors to enhance their transduction efficiency or to 
increase cell type-specific transduction24,25. The recently developed AAV2/2 variant 
7m8 was reported to penetrate the retina and transduce cells in all retinal layers 
following intravitreal delivery in adult mice26. To investigate the transduction 
efficiency of bipolar cells, we produced a 7m8 vector carrying eGFP under the CMV 
promoter. Wild type mice received intravitreal injections of the vector at P5, an age 
before the inner limiting membrane (ILM) is fully established. The ILM can act as a 
natural barrier in adult animals when AAVs are delivered intravitreally, preventing 
efficient penetration of viral particles into deep layers of the rodent retina27,28. Three 
weeks post injection we observed a widespread pan-retinal expression of eGFP (Figure 
3A). Higher magnification images showed strongly transduced ganglion and Mueller 
glia cells as well as more sparsely transduced photoreceptors (Figure 3C). 
Immunostaining for PKCα and single confocal images revealed that several rod bipolar 
cells expressed eGFP (Figure 3B, 3C’ white arrows). To visualise better the 
transduction of bipolar cells we injected wild type animals with a 7m8 vector carrying 
eGFP under the weak Purkinje cell protein 2 (PCP2) promoter29 (Figure S4A, S4A’) or 
the 4x enhanced Grm6 (Grm6) promoter25 driving expression in rod bipolar cells or all 
ON bipolar cells, respectively. Magnified single images showed that the majority of 
PKCα-positive bipolar cells and several cone ON bipolar cells (arrow heads), contained 
eGFP (Figure 3D, 3E). We quantified the proportion of transduced bipolar cells 
following the administration of 7m8 by flow cytometry. PCP2.Cre/td.tomato mice 
received intravitreal injections with 7m8.CMV.eGFP at P5 or P6 and we found that 
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approximately 65 % of the td.tomato-positive rod bipolar cells were positive for eGFP 
(Figure 3F). We further analysed the number of transduced photoreceptors and 
established that approximately 25 % of the CD73-positive photoreceptors expressed 
eGFP (Figure S4B, S4C). Due to the lack of specific markers labelling all cone bipolar 
cells we did not quantify the transduction of other types of bipolar cells.  
 
Intravitreal delivery of 7m8.CMV.hCLN6 slowed the loss of photoreceptor function 
and photoreceptor cells in Cln6nclf mice   
ERG recordings at 1 month following intravitreal injections of 7m8.CMV.hCLN6 in 
Cln6nclf mice at P5 to P6, demonstrated that mutant eyes that received a vector dose of 
1x1010 vg had significantly higher scotopic a-wave amplitudes than untreated eyes or 
eyes that received 7m8.null control vector. The ERG amplitudes decreased slightly but 
remained significantly higher in treated than in untreated or 7m8.null-treated eyes at 4, 
6 and 9 months. Representative scotopic ERG traces of a mutant mouse that received 
1x109 vg of 7m8.CMV.hCLN6 in one eye and no treatment in the contralateral eye are 
shown in figure 4B, demonstrating the striking difference in retinal function between 
treated (red traces) and untreated (black traces) eyes at 9 months (see also Figure S5A, 
Table S2). Histological assessment of the treated eyes at 6 months confirmed the 
expression of human CLN6 in cells of all retinal layers. Consistent with the ERG 
recordings, treated retinas had a thicker ONL, a better structure of photoreceptor OS 
and reduced activation of Mueller glia cells as indicated by DAPI, rhodopsin and GFAP 
staining, respectively (Figure 4C). Counts of DAPI-positive photoreceptor nuclei 
showed that the number of nuclei was higher with an average of 6 and 7 rows of nuclei 
in the low titre and high titre group compared with 4 rows in untreated mutant eyes 
(Figure 4D). At 6 months counts of PKCα-positive cells did not reveal any significant 
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changes between treated and untreated eyes (Figure 4E). Histological assessment at 9 
months confirmed the long-term expression of the therapeutic transgene in treated 
retinas. It also was apparent that whilst the retinal degeneration continues to progress 
from 6 to 9 months resulting in 2 remaining rows of photoreceptor nuclei in Cln6-
deficient mice, the number of photoreceptor nuclei was maintained following the 7m8 
treatment with 6 and 7 rows of nuclei in the two treatment groups (Figure 4F, 4G). 
Similarly, the quantification of rod bipolar cells showed that untreated eyes continued 
to lose PKCα-positive cells from 6 to 9 months, whereas treated retinas had 
significantly higher numbers of rod bipolar cells at 9 months as highlighted by 
immunostaining for PKCα (Figure 4F, 4G). We did not maintain any mice for longer 
than 9 months since motor and behavioural skills, body weight and survival deteriorated 
progressively as part of the natural disease progression in Cln6-deficient mice16. 
 
7m8-mediated supplementation of CLN6 in bipolar cells specifically rescued the 
photoreceptor degeneration in Cln6nclf mice 
To investigate whether the transduction of bipolar cells alone was sufficient to treat the 
photoreceptor degeneration in Cln6-deficient mice, we produced two 7m8.hCLN6 
vectors, one carrying the weak PCP2 promoter to drive expression in rod bipolar cells 
and one carrying the 4x enhanced Grm6 promoter to drive expression in all ON bipolar 
cells. Cln6nclf mice at P5 or P6 received intravitreal injections with either vector at a 
dose of 1x1010 vg/eye. At 4 months the scotopic a-wave amplitudes were significantly 
higher in Grm6.hCLN6-treated retinas, reduced slightly over time but remained 
significantly higher up to 9 months. Retinas treated with the PCP2.hCLN6 construct 
showed a weaker therapeutic effect and had significantly increased scotopic a-wave 
amplitudes only at 6 months (Figure 5A). Figure 5B shows representative scotopic ERG 
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traces of a 9 months old Cln6nclf mouse that received 7m8.Grm6.hCLN6 treatment in 
one eye and no treatment in the contralateral eye (see also Figure S5B, Table S3). We 
did not follow up on mice that received injections with 7m8.PCP2.hCLN6 for longer 
than 6 months in view of the limited beneficial effect. Analyses of the retinal histology 
showed that at 6 months hCLN6 was present in bipolar cells, rod OS had a better 
morphology and Mueller glia cell activation was reduced in PCP2.hCLN6- and 
Grm6.hCLN6-treated retinas (Figure 5C). Some ganglion cells appeared to express 
human CLN6 following the administration of 7m8.Grm6.hCLN6. This was surprising 
because no expression of eGFP was detected in the GCL when 7m8.Grm6.eGFP was 
administered to wild type mice (see Figure 3D, 3E). Grm6 promoter driven expression 
in RGCs has been described previously30. A possible explanation for the preferential 
expression of CLN6 over GFP in the GCL may be that the sequence of the CLN6 
transgene could contain elements that promote the ‘leaky’ activity of the Grm6 
promoter. In agreement with the functional restoration, the thickness of the ONL was 
increased in both treatment groups, however this only reached significance in 
7m8.Grm6.hCLN6-treated retinas with 6 rows of photoreceptor nuclei compared with 
4 rows in untreated mutant retinas at 6 months (Figure 5D). No significant difference 
in the number of rod bipolar cells was detected following the treatment at 6 months 
(Figure 5E), but at 9 months the number of PKC-positive cells was significantly 
increased (p = 0.0057) (Figure 5H) as highlighted by representative images in figure 
5F. From 6 to 9 months the rows of photoreceptor nuclei remained higher in the treated 




AAV-mediated gene therapies have proven a successful treatment strategy to combat 
photoreceptor degenerations in animal models carrying mutations in various genes8-10. 
Here, we described the development of a successful treatment for the retinal 
degeneration in Cln6-deficient mice, a model of NCL that carries a mutation in the Cln6 
gene, encoding a transmembrane ER protein of unknown function. We demonstrated 
that the photoreceptor degeneration in Cln6nclf mice was amenable to treatment when 
the therapeutic CLN6 transgene was delivered specifically to bipolar cells, a retinal cell 
type downstream of photoreceptors. The bipolar cells themselves were only lost at late 
disease stages after the majority of photoreceptors had died. The treatment with the 
ubiquitous promoter had the biggest beneficial effect, most likely because expression 
was achieved in all transduced bipolar cell subtypes. The administration of bipolar cell 
subtype-specific promoter constructs resulted in a slighter lower therapeutic effect. 
CLN6 deficiency in photoreceptors did not play a central role in the development or 
progression of the photoreceptor degeneration. 
 
For the successful treatment of the retinal phenotype in Cln6nclf mice, it was vital to 
understand the endogenous expression pattern of CLN6 in the retina. It was surprising 
that CLN6 is more highly expressed in bipolar cells than in photoreceptors since 
bipolars are not lost early in disease. Based on our data, a scenario could be envisaged 
where gene supplementation therapies targeting only the degenerating brain regions or 
the cell types that are lost early in the disease could be ineffective. Hence, for successful 
brain-directed gene therapies for CLN6 disease, variant late-infantile, it may be 
necessary to conduct a detailed analysis of the endogenous CLN6 expression in the 
different cell types and regions of the brain. Whilst brain-directed gene therapy for 
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CLN6-deficiency using a ubiquitous promoter, may be successful and may not require 
the targeting of specific cells, there is, however, a risk that wide-spread high level non-
specific expression of CLN6 may result in toxicity. The use of a specific promoter 
targeting the appropriate cells would decrease that risk. 
 
Retinal disorders arising from defects in bipolar cells are rare. One such disease is 
complete congenital stationary night blindness (cCSNB), caused by mutations in genes 
expressed in bipolar cells. These lead to a complete loss of the ERG b-wave that is 
accurately recapitulated in mouse models harbouring mutations in genes such as Grm6 
or Nyctalopin (Nyx)31,32. AAV-mediated gene transfer to the bipolar cells of a Nyx-
deficient mouse has previously been shown to partially restore bipolar cell function in 
this stationary disease33. In contrast to the phenotype observed in Cln6nclf mice, cCSNB 
does not result in a severe loss of photoreceptors. To our knowledge, this is the first 
report to describe a retinal dystrophy in which a gene defect in bipolar cells mediates 
the loss of photoreceptors whilst leaving the bipolar cells largely unaffected. The ERG 
recordings performed in our study did not resolve whether the decrease in the scotopic 
b-wave in untreated Cln6nclf mice was a result of the reduced rod photoreceptor 
function, an intrinsic reduction of rod bipolar cell function or a combination of both. 
Since the b-wave is dependent on the presence of the a-wave, it reflects photoreceptor 
function, synaptic transmission from photoreceptors to bipolar cells and bipolar cell 
function34. Therefore, it remains unclear whether bipolar cells, which are not lost at 
early disease stages in Cln6-deficient mice, function normally. It could be speculated 
that abnormal bipolar cell function could affect the function and viability of 
photoreceptors as these cells are metabolically very active and sensitive to intra- or 
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extracellular changes35, but further studies are required to determine the disease 
mechanism in Cln6-deficient mice.  
 
We have confirmed that in mice the intravitreal administration of the recently 
developed 7m8 vector in the first postnatal week led to a widespread transgene 
expression in all retinal layers including bipolar cells. However, larger animals such as 
non-human primates have a significantly thicker ILM posing a greater challenge for 
retinal transduction after intravitreal AAV administration. Following intravitreal 
injection in non-human primates, transduction by 7m8 vector appears to be limited to 
the fovea and retinal areas in close proximity to blood vessels26,36, although the 
efficiency of bipolar cell transduction was not assessed in these studies. It thus remains 
to be determined whether other vectors and/or approaches are required for efficient 
targeting of bipolar cells in large animals and for human applications. Alternative 
vectors able to transduce the bipolar in the murine retina have been described, including 
AAV2/8BP2 and tyrosine-mutated AAVs25,37. However, as for AAV 7m8, the 
efficiency with which these vectors can transduce bipolar cells in larger animals has 
proved insufficient, making them less attractive for clinical use36,37. 
 
The ultimate aim of this study was to investigate whether gene therapy is a potential 
strategy to treat the retinal degeneration in CLN6 disease, variant late-infantile. As 
lysosomal cross-correction does not occur for CLN6, an ocular AAV-mediated 
treatment of Cln6nclf mice presents a very similar challenge to deficiencies in CLN3 or 
other transmembrane defects of NCL. This study therefore also provides proof-of-
concept of gene therapy for CLN3 disease, juvenile, the most common form of NCL 
caused by a transmembrane protein defect. Of note is that once CLN3 disease patients 
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have lost vision it can take several years before they develop severe neurological 
symptoms, creating a time window for therapeutic interventions to treat the visual 
failure38. Recently, mutations in CLN3 were also linked to cases of non-syndromic 
retinal degeneration in five unrelated patient families, highlighting further the need for 
ocular treatments for this condition39.  
 
Here, we established that endogenous CLN6 is more highly expressed in bipolar cells 
than in photoreceptors in mouse and human retina, consistent with results from a 
microarray study on mouse retina20. The same microarray study indicates that Cln3 is 
expressed in a variety of retinal cell types with a striking abundance only in microglia20. 
In a Cln3 knock-in reporter mouse (Cln3lacZ/lacZ) X-gal staining was present in bipolar 
cells as early as P14 and expression in photoreceptors became evident from P2140. ERG 
recordings in Cln3-deficient mice showed electronegative retinal responses with a 
preserved a-wave, an approximately 30 % decrease in the b-wave and no significant 
cell loss at 12 months41. In vivo assessment of Cln3-deficient mice also revealed that 
the GCL (including IPL and the nerve fibre layer) and the INL were significantly 
thinner at 18 months than in wild type mice, while the outer retina measured from OPL 
to OS and from the RPE to the choroid did not show any differences42, which may 
indicate that morphological alterations occur only in the inner retina. In line with these 
findings, CLN3 disease patients present with an electronegative maximal response and 
only mild a-wave disturbances at the onset of the disease, pointing to an early inner 
retinal dysfunction38. Collectively, these data indicate that bipolar cells could play an 
important role, not only in CLN6 disease, but also in CLN3 disease. Although CLN6 
and CLN3 encode for proteins involved in different cellular processes with different 
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subcellular localisation2, the same strategy to deliver the therapeutic transgene to 





Cln6nclf mice were kindly provided by Prof. Thomas Braulke (UKE, Hamburg). 
C57BL/6J and PCP2.Cre mice were purchased from Harlan Laboratories (UK). 
PCP2.Cre mice were paired with td.tomato (flox.STOP.flox.td.tomato) mice and Cre 
positive litter was confirmed by genotyping. All mice were maintained under cyclic 
light conditions (12 h light-dark). If not further specified, the ages of adult mice ranged 
from 8-12 weeks. Animal experiments were performed in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research and the UK 
Home Office license (PPL 70/8120). 
 
Plasmid construct 
Human CLN6 (hCLN6) cDNA was cloned into a pD10 vector containing the CMV 
promoter. To drive expression in rod bipolar cells, the CMV promoter was replaced 
with the PCP2 (purkinje cell protein 2) promoter kindly provided by Prof John 
Oberdick (OSU, Ohio). To drive expression in all ON bipolar cells, CLN6 cDNA was 
cloned into the pD10 vector carrying the 4xGrm6 (4x enhanced mGluR6) promoter 
kindly provided by Botond Roska (FMI, Basel). To produce a null vector, the pD10 
backbone was used carrying an unrelated transgene without promoter and start codon.  
 
Production of rAAV and intraocular administration 
Recombinant AAV2/8 and 7m8 vector were produced through a triple transient 
transfection method and purified by affinity-based AVB Sepharose column (GE 
Healthcare, UK) as described previously43. Viral particle titres were determined by 
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qRT-PCR using primers aligning to the SV40 poly A tail of the genomic plasmid and 
a specific probe carrying a FAM dye label. Viral vector administration was performed 
under general anaesthesia using an operating microscope (Carl Zeiss) and a 34 gauge 
needle (Hamilton) as described10. A total volume of 1.5 μl or 1 μl rAAV was injected 
in juvenile (P9-P10) and early postnatal (P5-P6) animals, respectively. At least two 
eyes were left uninjected in every mutant cohort and no animal received the same 
treatment in left and right eye.   
 
Electroretinography (ERG) 
ERG recordings were obtained from both eyes in mutant and wild type animals using 
commercially available equipment (Espion ERG Diagnosys System) as described 
previously10. After dark adaptation overnight, scotopic examinations were performed 
under single-flash recording using increasing light intensities. Photopic single-flash 
recordings were obtained following 5 minutes of light adaptation at a background light 
intensity of 30 cd/m2. N represents the number of independent animal cohorts and n 
represents the number of eyes in independent animals. ERG data from the same wild 
type cohorts is presented in figure 2, 4, 5 to provide a reference. 
 
Tissue preparation  
Human paraffin sections of the mid-retina were provided by Dr Michael Powner (UCL, 
London). Institutional Review Board (IRB)/Ethics Committee approval was obtained 
from Dr Marcus Fruttiger (UCL, London). The tissue was fixed in 2% PFA and 
obtained as described previously44. 6 μm thick retinal sections were deparaffinised in 
xylene substitute (Sigma Aldrich) and rehydrated in alcohol gradients of 100%, 75%, 
50% and 30% followed by a final PBS wash. For antibody staining, the slides were 
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heated to 120°C in 90% glyercol and 10% citrate buffer pH 6.0. For mouse retinal 
sections the murine eyes were enucleated following cervical dislocation and cornea, iris 
and lens were removed. The eye cups were fixed in 4% PFA for 1-2h, cryoprotected in 
20% sucrose and flash frozen in OCT.    
 
Immunohistochemistry  
The slides were briefly washed in PBS and blocking buffer was employed containing 
5% NGS, 1% BSA and 0.1% Triton-X100. The samples were incubated in primary 
antibody diluted in blocking buffer at 4°C overnight. Sections were washed in PBS and 
incubated in secondary antibody diluted in blocking buffer. Subsequently sections were 
washed in PBS, washed with 600nM DAPI for 5 minutes and mounted in DAKO 
mounting media. The slides were stored in the dark at 4°C until imaging by confocal 
microscopy (Leica DM5500Q).   
 
Quantification of retinal cross sections 
Eyes were sectioned in a sagittal orientation (18μm) and collected on glass slides. 
Confocal images (275μm x 275μm) were taken from the superior and inferior 
midcentral retina of three sagittal cross sections on each slide. To assess the ONL 
thickness, three vertical columns of DAPI-positive photoreceptor nuclei were counted 
in each of the six single confocal images. The counts of PKCα-positive cells were 
performed on the corresponding projection images. PKCα counts in figure S1 were 
performed on stained sections using mouse anti-PKCα antibody (Sigma Aldrich). For 
all other PKCα counts, staining was performed using mouse anti-PKCα antibody (Santa 
Cruz). Counts included age-matched wild type controls. Researchers performing counts 
were masked to the genotype of the animals and treatment received.  
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Quantitative real-time RT-PCR (qRT-PCR) 
Total RNA was extracted from mouse retinas or FACS-sorted cell samples using the 
RNeasy® Mini Kit (Qiagen). The QuantiTect® Reverse Transcription Kit (Qiagen) was 
utilized to generate cDNA. qRT-PCRs were performed in 96 well plates in a PCR 
thermal cycler (Applied Biosciences 7900HT) using a 2x FastStart TagMan® Probe 
Mastermix assay (Roche) with a probe concentration of 100nm and a primer 
concentration of 200nm with the following primers:  
forward β-actin (5’-AAGGCCAACCGTGAAAAGAT-3’),  
reverse β-actin (5’-GTGGTACGACCAGAGGCATAC-3’),  
forward Cln6 (5’-AGAGCCACATGCCAGGAC-3’),  
reverse Cln6 (5’-GGCGAAGAAGGTGAAGATGA-3’),  
forward Peripherin2 (5’-TGGATCAGCAATCGCTACCT-3’) and  
reverse Peripherin2 (5’-CCATCCACGTTGCTCTTGA-3’). Triplicate reactions were 
carried out for each sample. The Ct values were calculated using the computer 
programme SDS 2.2.2 (Applied Biosciences). To determine relative expression levels, 
the Ct values of the triplicate reactions for every gene were averaged and normalized 
to the averaged β-actin Ct values of each corresponding sample (ΔCt). For absolute 
quantification, a dilution series of plasmid DNA ranging from 1.5 x 103 to 1.5 x 107 
molecules was used to produce a standard curve. A dilution series of wild type mouse 
retina cDNA was performed in the ratios of 1:10:100. The obtained Ct values were 
averaged per triplicate reaction and the number of specific cDNA molecules per 
nanogram total mRNA was calculated by standard curve intrapolation.  
 
Retinal semithin sections 
Eyes were enucleated, the cornea and lens removed. The eyecups were fixed in 
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Karnovsky fixative for least 30 hours at 4°C. The eyes were dehydrated by passage 
through ascending ethanol series (50-100%) and propylene oxide and infiltrated 
overnight with 1:1 mixture of propylene oxide: Epoxy resin. After further 8 hours in 
full resin, eyes were embedded in fresh resin and incubated overnight at 60°C. Semithin 
(0.7 μm) sections were cut in the inferior- superior axis passing through the optic nerve 
head using a Leica ultracut S microtome. Retinal semithin sections were stained with a 
1% mixture of toluidine blue-borax in 50% ethanol. Images were captured of the 
inferior and superior mid-retina from three sections per eye (in total six images per eye) 
using a Qimaging camera (MicroPublisher 5.0 RT) mounted on a light microscope 
(Leica DM IRB). Images were exported as TIFFs and measurements were performed 
in Image J.  
 
Fluorescence-activated cell sorting and flow cytometry analysis 
Cell sorting was performed using a BD Influx Cell SorterTM (Becton Dickinson 
Biosciences, USA) fitted with a 200mW 488 nm blue laser that was used to excite GFP 
detected in the 488-530/40nm channel, a 50mW 561 nm yellow/green laser that was 
used to excite tdTomato detected in the 561-585/29nm channel, and a 100mW 640nm 
red laser used to excite an anti-mouse CD73-APC antibody (BioLegend®, 127209) 
detected in the 640-670/30nm channel. Sorting of photoreceptors and bipolar cells was 
performed with a 70 micron nozzle at 50psi. To determine cell viability, DRAQ7TM 
(Biostatus, DR71000) dead cell stain was added to the samples at a final concentration 
of 0.6 µM for 5 minutes at room temperature. All of the samples were analysed using 
a BD LSRFortessaTM X-20 flow cytometer (Becton Dickinson Biosciences, USA), 
fitted with 5 lasers (i.e. 355nm, 405nm, 488nnm, 561nm & 640nm lasers). Results were 
subsequently analysed using FlowJo® software v. 9.9.5 (FlowJo, LLC). 
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Statistical analysis 
Data are represented as means ± SD (standard deviation) or ± SEM (standard error) 
with the appropriate n (number of independent samples) values as indicated. The 
appropriate tests and p values are provided in the figure legends with *: p < 0.05, **: p 
< 0.01, ***: p < 0.001.  
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Figure 1: CLN6 is more highly expressed in bipolar cells than in photoreceptors 
in human and mouse retina 
Staining for CLN6 (green) and PKCα (red) on human retinal section showing high 
levels of CLN6 in the INL and lower levels in the ONL with (A) and without (B) DAPI 
nuclear counter staining in blue. Grey boxes show areas of higher magnification 
images. Scale bar 50μm. (B’) Single confocal image revealing CLN6-positive rod 
bipolar cells (arrows) and (B’’) CLN6-positive cells in the ONL. Scale bar 25μm. (C) 
Cln6 expression level in adult mouse bipolar cells relative to photoreceptors after 
normalisation for ß-actin (mean ± SEM), n = 3 samples of 3-5 pooled retinas each (not 
significant, Mann-Whitney U test). (D) Absolute expression levels of Cln6 and 
Peripherin2 in adult wild type mouse retinas (means ± SEM). Peripherin2: n = 3 mice, 
Cln6nclf: n = 4 mice. (E) Time course of the expression level of Cln6 in wild type mouse 
retinas relative to adult levels, normalized for ß-actin (mean ± SEM, Kruskall-Wallis, 





Figure 2: Subretinal delivery of AAV2/8.CMV.hCLN6 did not rescue 
photoreceptors in Cln6nclf mice 
(A) Scotopic ERG a-wave amplitudes of Cln6nclf mice that received subretinal 
injections with AAV2/8.CMV.hCLN6 at P9-P11. Wild type: n = 5-7 eyes, N = 2; 
Cln6nclf untreated: n = 14-17 eyes, N = 5; null: n = 3-4 eyes, N = 1; 1.5x108 vg/eye: n = 
6 eyes, N = 1; 1.5x109 vg/eye: n = 7 eyes, N = 2; 1.5x1010 vg/eye: n = 6-8 eyes, N = 2. 
***: p < 0.001 (2-way ANOVA-Bonferroni post-test). (B-D) hCLN6 staining 
confirmed transgene expression in photoreceptors at 6 months after transduction with 
1.5x108 vg/eye (B) and high magnification (B’), 1.5x109 vg/eye (C) and high 




Figure 3: AAV 7m8 vector transduced mouse bipolar cells efficiently 
(A) Section of wild type mouse eye 3 weeks post intravitreal injection of 1x1010 vg 
7m8.CMV.eGFP at P5. Scale bar 250 m. (B-C) Higher magnification images of wild 
type retinas treated with 7m8.CMV.eGFP and immunostained for PKC (red) without 
(B) and with (C) the green channel shown. Scale bar 50 m. (C’) Single merged image 
of 7m8.CMV.eGFP-treated wild type retina showing transduced PKC-positive rod 
bipolar cells. Scale bar 25 m. (D) Section of wild type mouse eye 3 weeks post 
intravitreal injection of 1x1010 vg 7m8.Grm6.eGFP at P5. Scale bar 250 m. (E) Higher 
magnification image of 7m8.Grm6.eGFP-treated retina stained for PKC (red). Scale 
bar 50 m. (E’) Single image demonstrating transduction of the majority of PKC-
positive rod bipolar cells (arrows indicate non-transduced PKC-positive cells) and 
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some cone ON bipolar cells (arrowheads), identified by the location of their cell bodies 
in the INL and synaptic termini in the inner plexiform layer (IPL). Scale bar 25 m. (F) 
Quantification by flow cytometry of the proportion of rod bipolar cells transduced by 




Figure 4: Intravitreal administration of 7m8.CMV.hCLN6 slowed loss of 
photoreceptor function and photoreceptor cells in Cln6nclf mice 
(A) Scotopic ERG a-wave amplitudes of Cln6nclf mice after injection of 
7m8.CMV.hCLN6 at P5-P6. Wild type: n = 5-7 eyes, N =2; Cln6nclf untreated: n = 10-
11 eyes (1-6 months), N = 4, n = 5 (9 months), N = 2; null: n = 3-6 eyes, N =2; 1x109 
vg/eye: n = 11-13 eyes (1-6 months), N = 4, n = 5 (9 months), N = 2; 1x1010 vg/eye: n 
= 12 eyes (1-6 months), N = 4, n = 4 (9 months), N =2. p < 0.01 = **, p < 0.001 = *** 
(2-way ANOVA-Bonferroni post-test). (B) Scotopic ERG traces of a Cln6nclf mouse 9 
months after administration of 1x109 vg 7m8.CMV.hCLN6 in one eye (red). 
Contralateral uninjected eye in black. (C) hCLN6 staining (green) on treated and 
untreated eyes at 6 months. GFAP (white) and Rhodopsin (red) showed better 
morphology in treated eyes. (D) Quantification of photoreceptor rows and (E) PKC-
positive cells at 6 months. ***: p < 0.001 (Kruskal-Wallis test). (F) hCLN6 (green) and 
PKC (red) staining on treated and untreated eyes at 9 months. (G) Quantification of 
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photoreceptor rows and (H) PKC-positive cells at 9 months post treatment. **: p < 






Figure 5: hCLN6 delivery to bipolar cells slowed the loss of photoreceptor function 
and photoreceptor cells in Cln6nclf mice 
(A) Scotopic ERG a-wave amplitudes of Cln6nclf mice after injection of 
7m8.PCP2.hCLN6 or 7m8.Grm6.hCLN6 (1x1010 vg/eye) at P5-P6. p < 0.01 = **, p < 
0.001 = *** (2-way ANOVA-Bonferroni post-test). Wild type: n = 5-7 eyes, N = 2; 
Cln6nclf untreated: n = 7-9 eyes (1-6 months), N =3, n = 5 (9 months), N = 2; 
PCP2.hCLN6: n = 10-11 eyes, N = 4, Grm6.hCLN6: n = 14 eyes (1-6 months), N = 5, 
n = 7 (9 months), N = 3. (B) Scotopic ERG traces of a Cln6nclf mouse 9 months after 
administration of 1x1010 vg 7m8.Grm6.hCLN6 in one eye (red). Contralateral 
uninjected eye in black. (C) hCLN6 staining (green) on treated and untreated eyes at 6 
months confirmed transgene expression in bipolar cells. GFAP (white) and Rhodopsin 
(red) show better morphology in treated eyes. (D) Quantification of photoreceptor rows 
and (E) PKC-positive cells, 6 months post treatment. (F) hCLN6 (green) and PKC 
(red) staining on treated and untreated eyes at 9 months. (G) Quantification of 
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photoreceptor rows and (H) PKC-positive cells at 9 months post treatment. **: p < 
0.01 ***: p < 0.001 (Kruskal-Wallis test). Scale bars 25 m. 
 
